[Statins and their influence on inflammatory processes in internal carotid artery stenosis]

H Kunte1, N Amberger, R-I Rückert

  • 1Klinik für Neurologie der Charité-Universitätsmedizin Berlin, Berlin, Deutschland.

Insights

Statins may reduce perioperative complications in patients with high-grade carotid stenosis by stabilizing plaques and reducing inflammation. Preoperative statin use is increasingly supported for managing this high-risk condition.

Area of Science:

  • Vascular Biology and Atherosclerosis
  • Cerebrovascular Disease
  • Pharmacology

Context:

  • High-grade internal carotid artery stenosis is a primary cause of cerebral ischemia due to arterio-arterial emboli.
  • Inflammatory processes drive atherosclerotic plaque development and destabilization, increasing thrombosis risk.
  • Perioperative complications during carotid endarterectomy are a significant concern.

Purpose:

  • To explore the role of inflammation in carotid stenosis and its link to perioperative risks.
  • To evaluate the lipid-independent effects of statins, including plaque stabilization and improved cerebral autoregulation.
  • To assess the evidence supporting preoperative statin administration in patients with high-grade carotid stenosis.

Summary:

  • Inflammatory cells like macrophages contribute to carotid plaque instability via proinflammatory factors, matrix metalloproteinases, and tissue factor.
  • Statins, beyond cholesterol reduction, demonstrate plaque-stabilizing properties and enhance cerebral autoregulation.
  • Evidence suggests preoperative statins can mitigate risks associated with high-grade carotid stenosis and endarterectomy.

Impact:

  • Highlights the therapeutic potential of statins in managing high-risk carotid artery disease.
  • Informs clinical practice regarding the preoperative use of statins to improve patient outcomes.
  • Underscores the importance of targeting inflammatory pathways in cerebrovascular disease management.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...